Boehringer Ingelheim clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
36 trials changed in the last 30 days: 0 stopped, 10 with notable changes, 26 with minor changes only.
- Notable: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight Recruitment opened
- Notable: SYNCHRONIZE®-HERA · Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight Recruitment opened
- Minor: Beamion LUNG-3 · Adjuvant Zongertinib vs Standard Treatment · Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations Trial sites expanded: 202 → 205 locations
- Minor: ELEVATE-LIVER · Survodutide Helps Improve Heart Structure and Function · Overweight or Obesity and Fatty Liver Disease Trial sites expanded: 45 → 55 locations
- Notable: How Well BI 3000202 is Tolerated by · Type 1 Interferonopathies Primary completion pushed from Dec 6, 2026 to Dec 10, 2029
- Minor: People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body Primary and study completion dates pushed to Apr 9, 2027
- Minor: Find Out if BI 764198 Helps Adults and · a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) Trial sites reduced: 316 → 309 locations
- Minor: Survodutide Helps · Type 2 Diabetes Control Their Blood Sugar Trial sites expanded: 101 → 121 locations
- Minor: BI 3810477 Helps · Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment Trial sites expanded: 37 → 42 locations
- Notable: Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood Enrollment reduced: 16 → 10 participants
- Notable: DAREON®-36 · Obrixtamig in Combination With ZL-1310 · Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers Recruitment opened
- Notable: How Well Different Doses of BI 3821001 Are Tolerated by Healthy People Recruitment opened
- Minor: VERDANT · BI 771716 Helps · an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy Trial completed
- Minor: How BI 3000202 is Taken up in the Blood · and Without Liver Problems Trial completed
- Minor: Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States Primary and study completion pushed from Oct 30, 2026 to Jan 29, 2027
- Minor: AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps · Bronchiectasis Trial sites reduced: 478 → 474 locations
- Minor: LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps · a Liver Disease Called NASH/MASH Who Have Cirrhosis Trial sites expanded: 446 → 449 locations
- Minor: People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON) Trial sites expanded: 383 → 394 locations
- Minor: Survodutide Improves How the Body Uses Energy and Breaks Down Fat · Obesity Study completion moved earlier from Jan 10, 2027 to Dec 1, 2026
- Minor: Healthy People to Measure How Different Doses of Verducatib Affect the Heart Enrollment closed, study ongoing
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-16 | NCT07940244 A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations… | Phase 1 | Not Yet Recruiting |
| 2026-11-10 | NCT07929051 A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer… | Phase 3 | Not Yet Recruiting |
| 2026-11-09 | NCT07926308 Real-world Outcome of Zongertinib in Japan (J-HERZ) | Not Yet Recruiting | |
| 2026-11-09 | NCT07926321 A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When… | Phase 2 | Not Yet Recruiting |
| 2026-11-09 | NCT07926334 A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients… | Phase 1 | Not Yet Recruiting |
| 2026-11-04 | NCT07915219 A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With… | Phase 3 | Not Yet Recruiting |
| 2026-10-30 | NCT07907991 The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic… | Phase 3 | Not Yet Recruiting |
| 2026-10-30 | NCT07908004 A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People | Phase 1 | Recruiting |
Active trials by phase
| Phase 1 | 41 | |
| Phase 1/2 | 5 | |
| Phase 2 | 15 | |
| Phase 3 | 28 |
Not charted: 10 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 28
Lung Cancer (16) · Obesity (11) · Small Cell Lung Cancer (9) · Non-Small Cell Lung Cancer (NSCLC) (7) · Heart Disease (5) · Chronic Kidney Disease (4) · Diabetes (4) · Heart Failure (4) · NASH / MASH (4) · Idiopathic Pulmonary Fibrosis (3)
Get alerts when Boehringer Ingelheim's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.